Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 234 followers
Latest posts
Last updated 2 days ago
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
2 days ago
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced...
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance
4 days ago
2024 revenue is expected to be approximately $45.0 billion for the full...
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program
5 days ago
The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and...
Lilly to participate in J.P. Morgan Healthcare Conference
11 days ago
INDIANAPOLIS , Jan. 7, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Lilly commends ITC ruling cracking down on the unlawful importation and sale of knock-off tirzepatide products that put Americans at risk
26 days ago
Evidence of harmful knockoff tirzepatide escalates INDIANAPOLIS, December 23, 2024 – In...
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity
28 days ago
Averaging up to 20% of weight loss, adults taking Zepbound had at...
Lilly's Kisunla™ (donanemab-azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
about 1 month ago
China is the fourth major market where Kisunla has received approval Kisunla...
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
about 1 month ago
This milestone stems from the companies' collaboration to expand access to affordable...
Lilly's Omvoh® (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease
about 1 month ago
The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh...
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio® (abemaciclib) in Patients with ER+, HER2- Advanced Breast Cancer
about 1 month ago
As monotherapy, imlunestrant significantly reduced the risk of progression or death by...
Phase 3 results for Lilly's Jaypirca® (pirtobrutinib) in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting
about 1 month ago
Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease...
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase
about 1 month ago
INDIANAPOLIS , Dec. 9, 2024 /PRNewswire/ -- Today, the board of directors...